HIV antibodies block infection by reservoir-derived virus in laboratory study

August 26, 2014
Tae-Wook Chun, Ph.D., staff scientist in the NIAID Laboratory of Immunoregulation and first author of the study. Credit: NIAID

A laboratory study led by scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), lends further weight to the potential effectiveness of passive immunotherapy to suppress HIV in the absence of drug treatment. Passive immunotherapy for HIV is an experimental strategy that involves periodically administering broadly neutralizing HIV-specific antibodies (bNAbs) to control the virus. It would be advantageous to control HIV without antiretroviral drugs because of their cost, the potential for cumulative toxicities from lifelong therapy, and the difficulties some patients have adhering to drug regimens and tolerating certain drugs.

Although bNAbs have proven effective at blocking infection by various strains of HIV in the laboratory, their effect on HIV in humans, and particularly on the virus particles that hide in immune cells (called latent viral reservoirs), has been unknown.

In this study, NIH scientists obtained HIV from the latent reservoirs of 29 infected people in whom fully inhibited viral replication. In the laboratory, the researchers found that several bNAbs—particularly PGT121, VRC01 and VRC03 —effectively blocked HIV from entering the CD4+ T cells obtained from uninfected healthy donors. In addition, the scientists demonstrated in the laboratory that these antibodies could completely block HIV replication in CD4+ T cells obtained from infected individuals receiving antiretroviral therapy.

The researchers conclude that passive immunotherapy involving bNAbs individually or in combination may control HIV in the absence of antiretroviral therapy. A number of clinical trials are already underway or planned to test this hypothesis.

Explore further: Scientists create new tool for identifying powerful HIV antibodies

More information: T-W Chun, et al. Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. PNAS DOI: 10.1073/pnas.1414148111 (2014).

Related Stories

Research may be beating HIV, but a vaccine remains distant

July 11, 2014

Three decades since the onset of the infection in a global population, HIV care and treatment is looking very different. Given the difficulties involved, it is remarkable that having developed good treatments, the global ...

New research offers hope for HIV vaccine development

August 13, 2014

In a scientific discovery that has significant implications for HIV vaccine development, collaborators at the Boston University School of Medicine (BUSM) and Duke University School of Medicine have uncovered novel properties ...

Recommended for you

Videos reveal how HIV spreads in real time

October 2, 2015

How retroviruses like HIV spread in their hosts had been unknown—until a Yale team devised a way to watch it actually happen in a living organism. The elaborate and sometimes surprising steps the virus takes to reach and ...

Researchers find proteins that shut down HIV-1

September 30, 2015

A pair of studies by researchers at the University of Massachusetts Medical School, the University of Trento in Italy, and the University of Geneva in Switzerland, point to a promising new anti-retroviral strategy for combating ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.